Clinical trial · Interventional
Radiation Therapy in Treating Women With Localized Breast Cancer
Prospective Randomised Clinical Trial Testing 5.7 Gy and 6.0 Gy Fractions of Whole Breast Radiotherapy in Terms of Late Normal Tissue Responses and Tumour Control - FAST
NCT00107497CI-TRIAL-00037312FASTcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in different ways and giving it after surgery may kill any tumor cells that remain after surgery. PURPOSE: This randomized clinical trial is studying radiation therapy to see how well it works in treating women with localized breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiation therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Control
- description
- 50Gy in 25 fractions of radiation therapy over 5 weeks
- interventionNames
- Radiation: Radiation therapy
- type
- ACTIVE_COMPARATOR
- label
- Test group 1
- description
- 30Gy in 5 fractions of radiation therapy over 5 weeks
- interventionNames
- Radiation: Radiation therapy
- type
- ACTIVE_COMPARATOR
- label
- Test group 2
- description
- 28.5Gy in 5 fractions of radiation therapy over 5 weeks
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 50 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Diagnosis of invasive carcinoma of the breast
* Localized disease
* Pathological tumor size \< 3.0 cm in diameter
* Axillary node negative
* At average or low risk of local tumor recurrence
* Must have undergone prior breast-preserving surgery
* No prior mastectomy
* Complete microscopic resection of tumor
* Hormone receptor status:
* Not specified
PATIENT CHARACTERISTICS:
Age
* 50 and over
Sex
* Female
Menopausal status
* Not specified
Performance status
* Not specified
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* Not specified
Renal
* Not specified
Other
* Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* No prior neoadjuvant or adjuvant cytotoxic chemotherapy
Endocrine therapy
* Not specified
Radiotherapy
* No concurrent lymphatic radiotherapy
* No concurrent radiotherapy boost to the breast
Surgery
* See Disease CharacteristicsReferences
Publications (1)
- DERIVEDBrunt AM, Haviland JS, Sydenham M, Agrawal RK, Algurafi H, Alhasso A, Barrett-Lee P, Bliss P, Bloomfield D, Bowen J, Donovan E, Goodman A, Harnett A, Hogg M, Kumar S, Passant H, Quigley M, Sherwin L, Stewart A, Syndikus I, Tremlett J, Tsang Y, Venables K, Wheatley D, Bliss JM, Yarnold JR. Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer. J Clin Oncol. 2020 Oct 1;38(28):3261-3272. doi: 10.1200/JCO.19.02750. Epub 2020 Jul 14. PMID 32663119